(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation. The approval is based on … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acalabrutinib, AstraZeneca, autologous hematopoietic stem cell transplantation, bendamustine, blood cancers, Bruton’s tyrosine kinase, BTK inhibitor, Calquence, chemoimmunotherapy, COVID-19, Dave Fredrickson, ECHO Phase III trial, FDA, global regulatory review, international markets, Lymphoma Research Foundation, mantle cell lymphoma, MCL, Meghan Gutierrez, Michael Wang, oncology, PFS, progression-free survival, Project Orbis, regulatory submission, rituximab, safety profile, U.S. approval
The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release
Posted in Healthcare, Science, Sweden, Technology, United Kingdom
Tagged assisted ventilation, AstraZeneca, best supportive care, blood cancers, Bruton’s tyrosine kinase, BSC, BTK, BTK inhibitor, CALAVI, Calquence, clinical trial, COVID-19, cytokine storm, exaggerated immune response, inflammatory cytokines, José Baselga, Louis M. Staudt M.D. Ph.D., lung disease
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?